Roger S. Lo, MD., PhD
Roger S. Lo, MD., PhD
Professor of Medicine, Molecular and Medical Pharmacology
Verified email at mednet.ucla.edu
Title
Cited by
Cited by
Year
TGFβ signaling in growth control, cancer, and heritable disorders
J Massagué, SW Blain, RS Lo
Cell 103 (2), 295-309, 2000
29592000
Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation
R Nazarian, H Shi, Q Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ...
Nature 468 (7326), 973-977, 2010
22272010
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
19042016
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
17172016
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
16222012
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
13972011
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
M Krauthammer, Y Kong, BH Ha, P Evans, A Bacchiocchi, JP McCusker, ...
Nature genetics 44 (9), 1006-1014, 2012
11142012
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ...
New England Journal of Medicine 366 (3), 207-215, 2012
10322012
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery 4 (1), 80-93, 2014
8452014
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression
A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ...
Cell reports 19 (6), 1189-1201, 2017
7742017
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
7032017
Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ...
Nature communications 3 (1), 1-8, 2012
6822012
A Smad transcriptional corepressor
D Wotton, RS Lo, S Lee, J Massagué
Cell 97 (1), 29-39, 1999
6661999
A structural basis for mutational inactivation of the tumour suppressor Smad4
Y Shi, A Hata, RS Lo, J Massague, NP Pavletich
Nature 388 (6637), 87-93, 1997
6051997
Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4
A Hata, RS Lo, D Wotton, G Lagna, J Massague
Nature 388 (6637), 82-87, 1997
4841997
Determinants of specificity in TGF-β signal transduction
YG Chen, A Hata, RS Lo, D Wotton, Y Shi, N Pavletich, J Massagué
Genes & development 12 (14), 2144-2152, 1998
4821998
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5 (1), 1-15, 2014
4522014
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
4472015
Ubiquitin-dependent degradation of TGF-β-activated Smad2
RS Lo, J Massagué
Nature cell biology 1 (8), 472-478, 1999
4441999
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
K Trunzer, AC Pavlick, L Schuchter, R Gonzalez, GA McArthur, TE Hutson, ...
Journal of clinical oncology 31 (14), 1767-1774, 2013
3902013
The system can't perform the operation now. Try again later.
Articles 1–20